Effect of DC-CIK in combined with chemotherapy on the immunological function in patients with advanced non-small cell lung cancer

摘要

Objective: To explore the effect of DC-CIK in combined with chemotherapy on theimmunological function in patients with advanced non-small cell lung cancer (NSCLC).Methods: A total of 86 patients with NSCLC who were admitted in our hospital were includedin the study and randomized into the observation group and the control group with 43 cases ineach group. The patients in the two groups were given routine chemotherapy. On this basis, thepatients in the observation group were given DC-CIK cellular immunotherapy. The patients inthe two groups were treated for 3 courses. The peripheral blood T lymphocytes and cytokinesafter treatment in the two groups were compared. The clinical efficacy and adverse reactions inthe two groups were evaluated. Results: The total effective rate and disease control rate aftertreatment in the observation group were slightly higher than those in the control group, butthe comparison between the two groups was not statistically significant. CD8+ after treatmentin the observation group was significantly reduced, while CD3+, CD4+, and CD4+/CD8+ weresignificantly elevated when compared with before treatment. CD3+ and NK contents, andCD4+/CD8+ after treatment in the observation group were significantly higher than those in thecontrol group. IFN-γ, IL-4, TNF-毩 levels, and Th1/Th2 after treatment in the observationgroup were significantly higher than those in the control group, while TGF-毬 level wassignificantly lower than that in the control group. The occurrence rate of nausea and vomiting,and liver and renal function damage in the observation group was significantly lower than thatin the control group, but the median progression free survival (PFS) was significantly longerthan that in the control group, while the comparison of median overall survival (OS) betweenthe two groups was not statistically significant, and 2-year survival rate was significantlyhigher than that in the control group. Conclusions: DC-CIK in combined with chemotherapycan correct the immunologic disorder in patients with advanced NSCLC, and strengthen theanti-tumor effect.